ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Higher dementia risk linked to more use of common drugs

Top Anti-Inflammatory Foods, Herbs, and Spices

Latent HIV may lurk in 'quiet' immune cells, research suggests

Repair Damaged Mitochondria and Reduce Fatigue Up to 45%

Multiple sclerosis: pathological progression of the disease documented for the first time

Propolis - The Natural Antibiotic for MRSA, Candida, and More

Activate Your Natural Killer Cells

Microbiome linked to type 1 diabetes

Baylor Scientist Finds First Direct Evidence of Gene-Exposure Link in Gulf War Illness

Lyme disease costs up to $1. 3 billion per year to treat, study finds

 
Print Page
Email Article

Efficacy of pneumococcal vaccination in adults: A meta-analysis – Source: Canadian Medical Association Journal, Jan 6, 2009

  [ 9 votes ]   [ Discuss This Article ]
By Anke Huss, Matthias Egger, et al. • www.ProHealth.com • January 6, 2009


[Note: To read a pdf file of the full text article, click here. And to read a related commentary by other researchers cautioning that these conclusions “may exceed the evidence presented,” and don't warrant a change in vaccination policies, click here.]

Background: Clinical trials and meta-analyses have produced conflicting results of the efficacy of unconjugated pneumococcal polysaccharide vaccine in adults. We sought to evaluate the vaccine’s efficacy on clinical outcomes as well as the methodologic quality of the trials.

Methods: We searched several databases and all bibliographies of reviews and meta-analyses for clinical trials that compared pneumococcal polysaccharide vaccine with a control. We examined rates of pneumonia and death, taking the methodologic quality of the trials into consideration.

Results: We included 22 trials involving 101,507 participants: 11 trials reported on presumptive pneumococcal pneumonia, 19 on all-cause pneumonia and 12 on all-cause mortality. The current 23-valent vaccine was used in 8 trials. The relative risk (RR) was 0.64 (95% confidence interval [CI] 0.43–0.96) for presumptive pneumococcal pneumonia and 0.73 (95% CI 0.56–0.94) for all-cause pneumonia.

There was significant heterogeneity between the trials reporting on presumptive pneumonia (I2 = 74%, p < 0.001) and between those reporting on all-cause pneumonia (I2 = 90%, p < 0.001). The RR for all-cause mortality was 0.97 (95% CI 0.87–1.09), with moderate heterogeneity between trials (I2 = 44%, p = 0.053). Trial quality, especially regarding double blinding, explained a substantial proportion of the heterogeneity in the trials reporting on presumptive pneumonia and all-cause pneumonia. There was little evidence of vaccine protection in trials of higher methodologic quality (RR 1.20, 95% CI 0.75–1.92, for presumptive pneumonia; and 1.19, 95% CI 0.95–1.49, for allcause pneumonia in double-blind trials; p for heterogeneity > 0.05). The results for all-cause mortality in double-blind trials were similar to those in all trials combined.

There was little evidence of vaccine protection among elderly patients or adults with chronic illness in analyses of all trials (RR 1.04, 95% CI 0.78–1.38, for presumptive pneumococcal pneumonia; 0.89, 95% CI 0.69–1.14, for all-cause pneumonia; and 1.00, 95% CI 0.87–1.14, for all-cause mortality). [Note: an RR of 1.00 would indicate no difference between vaccinated & unvaccinated.]

Interpretation: Pneumococcal vaccination does not appear to be effective in preventing pneumonia, even in populations for whom the vaccine is currently recommended.

[Funding: World Health Organization]

Source: Canadian Medical Association Journal, Jan 6, 2009;180(1):48-58. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Institute of Social and Preventive Medicine University of Bern, Switzerland; Department of Geriatrics, Inselspital University Hospital, Bern; University Department of Geriatrics, Spital Netz Bern Ziegler, Bern; Department of Social Medicine University of Bristol, UK. [ E-mail: Matthias Egger, egger@ispm.unibe.ch]




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamins and Supplements

Featured Products

Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?
Research Links Green Tea to Weight Loss Research Links Green Tea to Weight Loss
Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue
Preserving Cognitive Function with Aging Preserving Cognitive Function with Aging

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing